HRP20211804T1 - Rad1901 za upotrebu u liječenju karcinoma jajnika - Google Patents
Rad1901 za upotrebu u liječenju karcinoma jajnika Download PDFInfo
- Publication number
- HRP20211804T1 HRP20211804T1 HRP20211804TT HRP20211804T HRP20211804T1 HR P20211804 T1 HRP20211804 T1 HR P20211804T1 HR P20211804T T HRP20211804T T HR P20211804TT HR P20211804 T HRP20211804 T HR P20211804T HR P20211804 T1 HRP20211804 T1 HR P20211804T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- tumor
- ovarian
- rad1901
- Prior art date
Links
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims 12
- 206010033128 Ovarian cancer Diseases 0.000 title claims 6
- SIFNOOUKXBRGGB-AREMUKBSSA-N (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1=CC(CCNCC)=CC=C1CN(CC)C1=CC(OC)=CC=C1[C@H]1CC2=CC=C(O)C=C2CC1 SIFNOOUKXBRGGB-AREMUKBSSA-N 0.000 title claims 5
- 150000001875 compounds Chemical class 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical group O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229950001573 abemaciclib Drugs 0.000 claims 1
- 229940087620 aromasin Drugs 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 208000011932 ovarian sarcoma Diseases 0.000 claims 1
- 229960004390 palbociclib Drugs 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 229950003687 ribociclib Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (12)
1. Spoj za upotrebu u inhibiranju rasta tumora ili dovođenja do regresije tumora kod subjekta koji ima karcinom jajnika ili tumor izabran iz grupe koja se sastoji iz karcinoma epitela jajnika, stromalnog karcinoma jajnika i karcinoma sarkoma jajnika, gdje je spomenuti spoj RAD1901 koji ima strukturu:
[image]
ili njegova sol ili solvat.
2. Spoj za upotrebu prema patentnom zahtjevu 1, gdje spomenuti karcinom jajnika ili tumor eksprimira ERα.
3. Spoj za upotrebu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje je karcinom ili tumor metastatski karcinom.
4. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1-3 pri čemu RAD1901 se daje u dnevnoj oralnoj dozi od između 100 i 1,000 mg, opcionalno gdje je dnevna doza 400 mg.
5. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, gdje je količina spomenutog spoja koji se daje 150 mg do 2,000 mg, opcionalno gdje je količina spomenutog spoja koji se daje 200 mg, 400 mg, ili 500 mg.
6. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1-5 gdje spomenuta upotreba dalje obuhvaća davanje taksana.
7. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 6, gdje je karcinom jajnika ili tumor rezistentan na lijek koji je odabran iz grupe koja obuhvaća anti-estrogene, inhibitore aromataze, i njihove kombinacije.
8. Spoj za upotrebu prema patentnom zahtjevu 7, gdje anti-estrogen je tamoksifen ili fulvestrant.
9. Spoj za upotrebu prema patentnom zahtjevu 7, gdje je inhibitor aromataze aromasin.
10. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1-9, koja dalje obuhvaća davanje subjektu terapeutski efikasne količine jednog ili više drugih terapeutskih sredstava izabranih iz grupe koja se sastoji iz inhibitora CDK4 i/ili CDK6 , opcionalno gdje su inhibitori CDK4 i/ili CDK6 izabrani iz grupe koja se sastoji iz ribocikliba, abemacikliba i palbocikliba.
11. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 10, gdje jedan ili više karcinom jajnika ili tumor subjekta je kirurški uklonjen prije početka davanja RAD1901.
12. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 11, gdje je subjekt u povećanom riziku da ima karcinom jajnika ili tumor, i davanje RAD1901 smanjuje šanse da subjekt dobije karcinom jajnika ili tumor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400495P | 2016-09-27 | 2016-09-27 | |
| EP17857371.3A EP3518911B1 (en) | 2016-09-27 | 2017-09-27 | Rad1901 for use in treating ovarian cancer |
| PCT/US2017/053834 WO2018064231A1 (en) | 2016-09-27 | 2017-09-27 | Methods for treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211804T1 true HRP20211804T1 (hr) | 2022-02-18 |
Family
ID=61760096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211804TT HRP20211804T1 (hr) | 2016-09-27 | 2017-09-27 | Rad1901 za upotrebu u liječenju karcinoma jajnika |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20200009085A1 (hr) |
| EP (1) | EP3518911B1 (hr) |
| JP (1) | JP2019532934A (hr) |
| KR (2) | KR20230152814A (hr) |
| CN (1) | CN109715149A (hr) |
| AU (1) | AU2017336564A1 (hr) |
| BR (1) | BR112019004276A2 (hr) |
| CA (1) | CA3036568A1 (hr) |
| CY (1) | CY1125266T1 (hr) |
| ES (1) | ES2898072T3 (hr) |
| HR (1) | HRP20211804T1 (hr) |
| HU (1) | HUE057064T2 (hr) |
| IL (1) | IL265537B2 (hr) |
| LT (1) | LT3518911T (hr) |
| MX (1) | MX2019003311A (hr) |
| PL (1) | PL3518911T3 (hr) |
| PT (1) | PT3518911T (hr) |
| RS (1) | RS62660B1 (hr) |
| SG (2) | SG11201901759XA (hr) |
| SI (1) | SI3518911T1 (hr) |
| WO (1) | WO2018064231A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230109666A2 (en) * | 2019-07-07 | 2023-04-06 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| CN1927815A (zh) * | 2006-09-25 | 2007-03-14 | 天津理工大学 | 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途 |
| EP2171447A1 (en) * | 2007-06-12 | 2010-04-07 | Schering Corporation | Histone h2ax (hh2ax) biomarker for fti sensitivity |
| GB201217439D0 (en) * | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
| BR112015030595A2 (pt) * | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| CN104436194B (zh) * | 2013-09-18 | 2018-03-30 | 北京大学 | 具有协同增效作用的抗癌组合物 |
| WO2015136016A2 (en) * | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| US9421264B2 (en) * | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| KR20230113416A (ko) * | 2014-12-18 | 2023-07-28 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도 |
| CN105848374A (zh) * | 2015-01-12 | 2016-08-10 | 芋头科技（杭州）有限公司 | 一种灯光控制***及方法 |
| EP4056127A1 (en) * | 2015-01-28 | 2022-09-14 | DePuy Synthes Products, Inc. | Battery enclosure for sterilizeable surgical tools having thermal insulation |
| IL307981A (en) * | 2015-04-29 | 2023-12-01 | Radius Pharmaceuticals Inc | Cancer treatment methods |
-
2017
- 2017-09-27 PL PL17857371T patent/PL3518911T3/pl unknown
- 2017-09-27 HU HUE17857371A patent/HUE057064T2/hu unknown
- 2017-09-27 AU AU2017336564A patent/AU2017336564A1/en not_active Abandoned
- 2017-09-27 SI SI201730975T patent/SI3518911T1/sl unknown
- 2017-09-27 RS RS20211355A patent/RS62660B1/sr unknown
- 2017-09-27 CN CN201780058319.1A patent/CN109715149A/zh active Pending
- 2017-09-27 US US16/336,358 patent/US20200009085A1/en not_active Abandoned
- 2017-09-27 SG SG11201901759XA patent/SG11201901759XA/en unknown
- 2017-09-27 EP EP17857371.3A patent/EP3518911B1/en active Active
- 2017-09-27 KR KR1020237036736A patent/KR20230152814A/ko not_active Application Discontinuation
- 2017-09-27 HR HRP20211804TT patent/HRP20211804T1/hr unknown
- 2017-09-27 MX MX2019003311A patent/MX2019003311A/es unknown
- 2017-09-27 JP JP2019515854A patent/JP2019532934A/ja active Pending
- 2017-09-27 BR BR112019004276A patent/BR112019004276A2/pt not_active Application Discontinuation
- 2017-09-27 PT PT178573713T patent/PT3518911T/pt unknown
- 2017-09-27 SG SG10202104282SA patent/SG10202104282SA/en unknown
- 2017-09-27 CA CA3036568A patent/CA3036568A1/en active Pending
- 2017-09-27 KR KR1020197011747A patent/KR20190058568A/ko not_active Application Discontinuation
- 2017-09-27 LT LTEPPCT/US2017/053834T patent/LT3518911T/lt unknown
- 2017-09-27 IL IL265537A patent/IL265537B2/en unknown
- 2017-09-27 ES ES17857371T patent/ES2898072T3/es active Active
- 2017-09-27 WO PCT/US2017/053834 patent/WO2018064231A1/en unknown
-
2021
- 2021-11-24 CY CY20211101023T patent/CY1125266T1/el unknown
-
2022
- 2022-12-27 US US18/089,092 patent/US20230129787A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019004276A2 (pt) | 2019-06-04 |
| KR20190058568A (ko) | 2019-05-29 |
| SG11201901759XA (en) | 2019-04-29 |
| KR20230152814A (ko) | 2023-11-03 |
| CN109715149A (zh) | 2019-05-03 |
| LT3518911T (lt) | 2021-12-10 |
| CA3036568A1 (en) | 2018-04-05 |
| JP2019532934A (ja) | 2019-11-14 |
| SI3518911T1 (sl) | 2022-02-28 |
| EP3518911A4 (en) | 2020-05-13 |
| RU2019108382A3 (hr) | 2020-12-28 |
| IL265537A (en) | 2019-05-30 |
| SG10202104282SA (en) | 2021-06-29 |
| ES2898072T3 (es) | 2022-03-03 |
| AU2017336564A1 (en) | 2019-03-14 |
| RS62660B1 (sr) | 2021-12-31 |
| CY1125266T1 (el) | 2023-03-24 |
| EP3518911A1 (en) | 2019-08-07 |
| IL265537B (en) | 2022-12-01 |
| EP3518911B1 (en) | 2021-08-25 |
| US20230129787A1 (en) | 2023-04-27 |
| PL3518911T3 (pl) | 2022-02-07 |
| HUE057064T2 (hu) | 2022-04-28 |
| PT3518911T (pt) | 2021-11-11 |
| US20200009085A1 (en) | 2020-01-09 |
| WO2018064231A1 (en) | 2018-04-05 |
| IL265537B2 (en) | 2023-04-01 |
| MX2019003311A (es) | 2019-07-08 |
| RU2019108382A (ru) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| Bayati et al. | Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells | |
| RU2017140674A (ru) | Способы лечения рака | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| Peng et al. | Ginsenoside 20 (S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway | |
| Islam et al. | Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer | |
| HRP20211177T1 (hr) | Korteksolon 17alfa-valerat za uporabu u liječenju tumora | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| AR110728A1 (es) | Terapia combinada para el tratamiento del cáncer | |
| RU2011104570A (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| Haddad et al. | Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer | |
| JP2019533651A5 (hr) | ||
| BR112018007947A2 (pt) | uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash | |
| UY38096A (es) | Inhibidores de arginasa y sus métodos de uso | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| JP2019530706A5 (hr) | ||
| BR112019006329A2 (pt) | métodos de tratamento de câncer do trato biliar | |
| MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
| JP2019532047A5 (hr) | ||
| HRP20211804T1 (hr) | Rad1901 za upotrebu u liječenju karcinoma jajnika | |
| BR112018008076A2 (pt) | derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos | |
| RU2015114967A (ru) | Производные ингенола, применяемые для лечения рака | |
| EP3817774A4 (en) | COMPOSITIONS AND METHODS FOR THE TOPICAL ADMINISTRATION OF PHARMACEUTICAL AGENTS FOR TREATING CANCER |